Skip to main content
. 2022 Apr 1;10:820229. doi: 10.3389/fped.2022.820229

Table 2.

Longitudinal Outcomes MIS-C.

Farooqi et al.
(n = 45)
Capone et al.
(n = 50)
Barris et al.
(n = 16)
Penner et al.
(n = 46)
Matsubara et al.
(n = 60)
Follow up (months) 5.8 (IQR 1.3–6.7) 6–8 7 (IQR 6.0–8.4) 6 3–6
Cardiovascular
Any echo abnormality (at least mild)
Admission 80 66 NA 33 NA
Short Term 18 21 NA NA NA
Mid Term 8 4 NA 4
Tricuspid Valve regurgitation 27 NA NA
Admission 60 NA
Short Term 15 NA
Mid Term 4 NA
Mitral valve regurgitation
Admission 36 NA NA NA
Short Term 78 NA
Mid Term 4 NA
Left ventricular systolic dysfunction
Admission 49 52 44 NA NA
Short term 10 2 13 NA
Mid term 4 0 0 0 NA
Coronary artery dilation or aneurysm
Admission 16 24 19 7
Short term 0 2 6 4 2
Mid term 0 0 6 4 0
Pericardial effusion
Admission 44 NA NA 2
Short term 10 NA NA 2
Mid term 0 NA NA 2
CMR performed NA 22 56 NA 23
Timing of MRI (post-admission) NA 2–4 weeks 9.4 (Range: 8.8–10.0) months NA 5 days−9.5 months
Myocardial edema NA 0 44 NA 21
Fibrosis NA 0 0 NA 14
6-min walk exercise test (abnormal)
6 weeks NA NA NA 65 NA
6 month NA NA NA 45 NA
Gastrointestinal
Symptoms
Admission NA NA NA 98 NA
Mid term NA NA NA 13 NA
Significant imaging findings NA NA NA 33 NA
Labs (weeks to normalization post-discharge)
Troponin 1–4 2 NA 6 NA
BNP 1–4 2 NA 6 NA
Platelets 0 8 NA 6 NA
CRP 1–4 2 NA 6 NA

NA, not available.

Numbers represent % of sample unless otherwise stated. Continuous variables are reported as median (IQR or Range) or mean ± standard deviation. Categorical variables are reported as percent of study sample.